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purposes, prIrinotecan (IRT) is an antineoplastic agent widely used in the treatment of various cancers primarily in colorectal cancer.
A new, simple and sensitive high-performance liquid chromatography (HPLC) method coupled with fluorescence detector
was developed and validated to quantify IRT and its active metabolite SN38 in the plasma of non-obese diabetic/severe
combined immune-deficient mice (NOD/SCID) mice bearing colon tumor. The plasma samples were extracted by precipi-
tation method using acetonitrile with 0.1% formic acid. The chromatographic separation was achieved using mobile phase
consisted of water and acetonitrile (57:43 v/v) pH 3 at the flow rate of 0.8 mL/min in C18 column (internal diameter,
250 × 4.6 mm; pore size, 5 μm). The method was validated according to the bioanalytical guidelines defined by Food and
Drug Administration (FDA) and European Medicine Agency (EMA). A regression (R2) value of 0.999 and 0.997 for IRT
and SN38 suggested the good linearity in the range of 0.1–10 μg/mL and 5–500 ng/mL, respectively. The calculated lower
limit of quantification (LLOQ) and limit of detection (LOD) for IRT were 0.1 and 0.065 μg/mL, respectively. However,
for SN38, LLOQ and LOD were 5 and 2 ng/mL, respectively. The intra-day and inter-day variations (coefficient of vari-
ance; % CV) observed during the validation were found to be within the set limit of 15%. Both accuracy and percentage
recovery analyzed and calculated from the quality control samples were in the between the defined range of 85–115%.
Plasma samples were found to be stable when stored at room temperature for 2 h, after 2 freeze–thaw cycles and at
−80 °C for 2 months. The developed method was successfully applied to study the plasma elimination profile of IRT in
NOD/SCID mice with tumor. The results from plasma concentration time profile and pharmacokinetic parameter analyzed
suggested the rapid elimination of IRT and SN38 from the plasma of NOD/SCID mice.
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Irinotecan (IRT) is an anticancer agent derived from natural
alkaloid camptothecin obtained from plant Camptotheca acuminate
[1]. It is approved by Food and Drug Administration (FDA) as the
first line treatment for metastatic colorectal cancer either alone or
in combination with other chemotherapeutic agents (i.e., FOLFIRI:
5-fluorouracil, lecovorine, and irinotecan) or monoclonal anti-
bodies (cetuximab, bevacizumab, and pantimumab) [2, 3]. Other
than colorectal cancer, it is also broadly used in lymphoma, leuke-
mia, breast, pancreatic, ovarian, brain, and small-cell lung cancer
[4, 5]. IRT exhibits its anticancer activity by inhibiting topo-
isomerase I and stabilizes the complex formed during the DNA
replication resulting into the cell death [6]. IRT (7-ethyl-10-[4-
(1-piperidino)-1-piperidino]carbonyloxycamptothecin) acts as a
prodrug and is converted by enzyme carboxylesterase (present
in liver, intestine, plasma, saliva) into highly active metabolite
SN38 (7-ethyl-10-hydroxycamptothecin; Figure 1) [7]. Com-
pared to the parent drug (IRT), SN38 is 100–1000 times more
cytotoxic [8, 9].
IRT is a potent anticancer agent but has various gastrointes-
tinal toxicities such as severe diarrhea, nausea, and vomiting
[10]. It also causes reduction in the white and red blood cells
count [11]. These side effects have significantly shifted the in-
terest of researchers towards the development of novel drugcorrespondence: ksingh1@uclan.ac.uk, profkksingh@gmail.com
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ferent nanoparticles (NPs) including nanoliposomes [12, 13],
poly(lactide-co-glycolic acid) (PLGA) NPs [14], solid lipid
NPs [15], magnetic NPs [16], and human serum albumin-
based NPs [17] of IRT have been developed and investigated
for their anticancer potential in xenograft models. Onivyde,
the liposomal formulation of IRT, was approved by FDA in
October, 2015 for the treatment of metastatic pancreatic cancer
following gemcitabine-based therapy [18, 19]. Novel IRT con-
jugates including XMT-1001 and CRLX101 are in the clinical
trials for the treatment of advance cancer [20, 21].
The human tumor xenograft models are commonly used for
preclinical assessment to screen the anticancer activity and es-
tablish pharmacokinetics (PK) of the existing drug or newly
developed formulations [22, 23]. These models involve human
cancer cell lines or tumor xenograft grown subcutaneously in
immune-deficient host such as nude or nonobese diabetic/se-
vere combined immune-deficient mice (NOD/SCID) and used
for pharmacodynamic (PD) studies [24, 25]. The pharmacoki-
netic studies are usually preferred to be performed in these
preclinical tumor xenograft models to explore the absorption,
distribution, and elimination of the drug and new advanced
formulations and determine PK/PD relationships before pro-
gressing to clinical trials. Also mouse models are more appeal-
ing than big animal models because of the ease-of-handling,
low cost, and known genetic information [26]. The present re-
search work aims towards the development and validation ofActa Chromatographica
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Figure 1. Structure of irinotecan and SN38
Development of HPLC method for Irinotecan and SN-38analytical method for the determination of IRT and its metab-
olite SN38 in the plasma of NOD/SCID mice (human colon
cancer xenograft model). There are several analytical tech-
niques available such as high-performance liquid chromatog-
raphy (HPLC) and liquid chromatography–mass spectroscopy
(LC–MS) for the determination of IRT and its metabolite in
biological samples [27, 28]. However, the method developed
by LC–MS is one of the expensive approaches and also in-
cludes the lengthy sample preparation time and extraction
procedure [29]. Therefore, liquid chromatography was chosen
over it for the method development of IRT and SN38. There
are reports of quantification of IRT and SN38 by HPLC
[30–32], but a very few studies have been published for the
quantification of IRT in rats and mice plasma [33, 34]. How-
ever, to the best to our knowledge, there are no reports for
analytical determination of IRT and SN-38 in tumor xeno-
graft mice models. Therefore, to understand the plasma elimi-
nation profile of IRT and its active metabolite in the NOD/
SCID mice xenograft model, a new method was preferably
established using reverse-phase HPLC coupled with fluores-
cence detector. The method was successfully developed, vali-
dated, and applied to measure the levels of IRT and SN38 in
colon tumor bearing NOD/SCID mice plasma to establish the
pharmacokinetics following intravenous administration of IRT
at the dose of 20 mg/kg.
2. Materials and Method
2.1 Reagents and Chemicals. Irinotecan hydrochloride
trihydrate was obtained as a gift sample from Khandelwal Lab.
Pvt. Ltd., Mumbai, India. SN38 and flurbiprofen were kindly
provided by Piramal, Mumbai, India. Acetonitrile (ACN), ACN
with 0.1% formic acid and orthophosphoric acid of HPLC grade,
were procured from Merck Ltd., Mumbai, India. Milli-Q grade
water purified by Milli-Q UV purification system (Millipore,
Bedford, MA, USA) was used throughout the experiments.
Dimethyl sulfoxide (DMSO) was purchased from Sigma,
Mumbai, India.22.2 HPLC Method Development
2.2.1 Instrument and Chromatographic Conditions. The
high-performance liquid chromatographic system (JASCO LC-
Net II/ADC, Japan) consisting of gradient flow control pump,
autosampler, column oven, and fluorescence detector was used
for the method development. All the parameters of HPLC were
controlled by ChromNav software. The chromatographic sepa-
ration was achieved using BDS Hypersil C 18 column (internal
diameter, 250 × 4.6 mm; pore size, 5 μm; Thermo scientific,
USA) with column temperature of 40 °C. The mobile phase con-
sisted of water and ACN (57:43), pH adjusted to 3 with 0.5%
orthophosphoric acid, and flow rate was kept at 0.8 mL/min.
The mobile phase was filtered through 0.45 μm filter and deaer-
ated for 15 min by sonication before use. IRT was detected on
fluorescence detector (FP-2020 plus, Japan) using excitation
(λex) and emission (λem) wavelength of 250 nm and 350 nm, re-
spectively. However, SN38 was detected at the λex of 370 nm
and λem of 525 nm. Flurbiprofen was used as internal standard
(IS) for both analytes.
2.2.2 Preparation of Stock and Standard Working Solution.
The stock solutions of IRT, SN38, and flurbiprofen were pre-
pared in DMSO at the concentrations of 1000 μg/mL for IRT,
50 μg/mL for SN38, and 1000 μg/mL for flurbiprofen, respec-
tively. These stock solutions were stored at −80 °C till further
used. Standard working solutions were prepared by serial dilution
of stock solutions in water at the concentrations of 200, 100, 50,
20, 10, 5, and 2 μg/mL for IRT and 1000, 500, 200, 100, 50, 20,
and 10 ng/mL for SN38 (Table 1), respectively. For flurbiprofen,
the working solution of 100 μg/mL was prepared in water. The
aliquots of these working solution were further stored in polypro-
pylene tubes at −80 °C. As presented in Table 1, the final calibra-
tion samples were prepared by spiking 5 μL of respective
standard working solution of IRT and 5 μL of IS into 90 μL of
blank NOD/SCID mice plasma to obtain the final plasma con-
centrations of 0.1, 0.25, 0.5, 1, 2.5, 5, and 10 μg/mL of IRT and
5 μg/mL IS, whereas for the preparation of SN38 calibration
curve, 90 μL of plasma was spiked with respective 5 μL of
SN38 standard working solution and 5 μL of IS to give the final
Table 1. Preparation of working and final solutions
Sr.
no.
IRT (stock solution: 1000 μg/mL) SN38 (stock solution: 50 ng/mL) Flurbiprofen (1000 μg/mL)
Working solution
(WS) conc.
Final conc.
(5 μL of WS + 90 μL of plasma)
Working solution
(WS) conc.
Final conc.
(5 μL of WS + 90 μL of plasma)
Working solution
(WS) conc.
Final
conc.
1 200 10 10,000 500 100 5
2 100 5 5000 250
3 50 2.5 2000 100
4 20 1 1000 50
5 10 0.5 500 25
6 5 0.25 200 10
7 2 0.1 100 5
N. Taneja et al.SN38 plasma concentrations of 5, 10, 20, 50, 100, 250, and
500 ng/mL. Calibration samples were prepared freshly from the
standard working solution every day during the validation pro-
cess. Quality control (QC) samples were prepared in plasma at
three concentrations (low, medium, and high) of 0.5, 2.5, and
5 μg/mL for IRT and 10, 50, and 250 ng/mL for SN38 from
their respective working solutions.
2.2.3 Preparation of Plasma Samples. The plasma samples
were thawed in ice bath, vortexed for 10 s, and centrifuged at
10,000 rpm for 10 min at 4 °C. In order to extract IRT and
SN38 from plasma samples, 1000 μL of ACN with 0.1% for-
mic acid was added to 95 μL of plasma sample spiked with
5 μL of IS. Mixture was allowed to stand for 5 min, vortexed,
and then centrifuged at 10,000 rpm for 10 min. Next, 900 μL
of supernatant was transferred to new labeled polypropylene
tubes and dried under nitrogen gas in Centrivap (Labconco,
USA) at 40 °C for 1 h. The dried samples were then reconsti-
tuted with 100 μL of water–ACN (80:20 v/v), vortexed, and
again centrifuged at 10,000 rpm for 10 min. Supernatant was
collected and diluted appropriately where required and col-
lected in HPLC vials for the injection. To prevent the carry
over effect, blank samples were run after every 3 samples dur-
ing the analysis.
2.3 Method Validation. The developed analytical method
was validated for specificity, linearity, sensitivity, precision,
and accuracy according to the bio-analytical guidelines
specified by US FDA and EMA [35, 36].
2.3.1 Selectivity. The selectivity of the method was
assessed by analyzing six samples for each of the following:
blank plasma, plasma samples spiked with IRT (2.5 μg/mL),
and SN38 (50 ng/mL) separately. All samples were detected
at λex = 250 nm and λem = 350 nm, and λex = 370 nm and
λem = 525 nm to determine any interference in detection of the
two analytes with each other at these wavelengths. Plasma sam-
ples obtained after intravenous injection of IRT to NOD/SCID
mice spiked with IS were also analyzed.
2.3.2 Calibration Curve. A calibration curve is the direct re-
lationship between response and concentration of analyte and is
used as a standard curve to determine the unknown concentration
of analyte in plasma. The linearity of calibration curves was
established and validated by conducting six runs of calibration
samples during validation. The calibration curve in plasma for
IRT was prepared using seven different concentrations of 0.1,
0.25, 0.5, 1, 2.5, 5, and 10 μg/mL, respectively, whereas for
SN38 concentrations of 5, 10, 20, 50, 100, 250, and 500 ng/mL
were employed. The calibration curve was obtained by plotting
the ratio of peak area of analyte (IRT, SN38) to the peak area of
IS versus concentrations of analyte in mice plasma. The curve
was further analyzed using linear least square regression to calcu-
late slope, intercept, and regression coefficient (R2).
2.3.3 Limit of Detection and Limit of Quantification. The
limit of detection (LOD) and lower limit of quantification
(LLOQ) were determined at the signal to noise ratio of 3:1 and
10:1, respectively. The LLOQ is the concentration of analyte that
is identifiable, reproducible, and can be back calculated with pre-
cision value (coefficient of variance; % CV) not exceeding 20%of the nominal concentration. LLOQ was established by analyz-
ing five samples and determining the % CV.
2.3.4 Accuracy, Precision and Recovery. Accuracy repre-
sents the closeness of the mean test results obtained from the ex-
periment to the actual concentration of analyte. The accuracy of
the method was assessed by analyzing the quality control sam-
ples for IRT (0.5, 2.5, 5 μg/mL) and SN38 (10, 50, 250 ng/mL)
for five times per calibration curve for six calibrations and devia-
tion of mean from nominal value was measured. The precision
of the analytical method describes the closeness of the results
obtained when the procedure is applied multiple times for the an-
alyte quantification. The intra-day variability of the method was
calculated by comparing the results obtained from five replicates
of QC concentration in one single analytical run on the same
day. However, to measure inter-day variations, QC samples were
run on different time and day.
The recovery of analyte can be defined as the ratio of added
analyte concentration obtained from plasma to the true concentra-
tion of analyte in solvent. The extraction efficiency (% recovery)
of the developed method was calculated by running the extracted
QC samples in five replicates, and the area was compared to the
unextracted standard that represents the 100% recovery.
2.3.5 Dilution Test. Samples at higher concentration than
the upper limit of quantitation need to be diluted prior to anal-
ysis. However, the dilution should not affect the reliability of
quantitation. To establish dilution integrity of samples (dilu-
tion factor 10×), spiked QC sample (5 μg/mL) in plasma was
diluted 10 times to give diluted QC sample. Five replicates of
dilution QC were analyzed within an analytical run.
2.3.6 Stability. Stability of drug in plasma is a function of
storage condition and should be evaluated during handling,
short-term and long-term storage, and after freeze–thaw cycles
[37]. To evaluate the stability of IRT and SN38 in plasma, QC
samples were analyzed during sample storage and handling.
Bench-top stability of samples was determined by analyzing the
samples after 2 h at room temperature. The stability of the pro-
cessed samples in autosampler was assessed by repeatedly ana-
lyzing these samples after 24 and 48 h of first injection. For
freeze–thaw stability, the freshly prepared QC samples were pro-
cessed and analyzed followed by the analysis of samples after
two freeze–thaw cycles. Long-term stability of plasma samples
was tested after storing the samples in −80 °C for 2 months. The
analyte is considered to be stable if the difference between the
freshly prepared and stability samples does not deviate more than
15% from the nominal concentration [37].
2.4 Application to Pharmacokinetic Study
2.4.1 Animals. Female NOD/SCID mice with body weight
of 18–22 g and 5–7 weeks of age were housed at Advanced
Center for Treatment Research and Education in Cancer
(ACTREC, Navi Mumbai, India). All experiments were car-
ried out according to the protocol approved by the Institu-
tional Animal Ethics Committee (IAEC) of ACTREC
(proposal number: 26/2015). Mice were kept in a specific
pathogen-free environment with 12:12 h light–dark cycle and
were provided with unrestricted access to food and water ad
libitum.3
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was used to study the plasma concentration time profile in female
NOD/SCID mice with colon tumor. Mice (n = 5) were injected
intravenously with IRT at the dose of 20 mg/kg and blood was
collected in ethylenediaminetetraacetic acid (EDTA) tubes by
retro-orbital puncture after 0.25, 0.50, 1, 2, 4, 6, 8, and 12 h of
dose administration. Samples were centrifuged at 10,000 rpm for
10 min to separate plasma and stored at −80 °C until analysis.
3. Results and Discussion
3.1 Method Optimization. Various preliminary experiments
were carried out to develop the analytical method for the
detection of IRT and SN38. For the extraction of analytes from
plasma samples, ACN with 0.1% of formic acid was added in
order to precipitate the proteins present in plasma. The extraction
efficiency using ACN with 0.1% of formic acid was found to be
85%, and no interfering peaks were observed. Moreover, other
variables including temperature and time under the nitrogenFigure 2. HPLC chromatogram of (a) blank plasma λex = 250 nm, λem = 3
350 nm; (c) blank plasma λex = 370 nm, λem = 525 nm; (d) plasma spiked with
IRT (2.5 μg/mL) λex = 370 nm, λem = 525 nm; (f) plasma spiked with SN38
(5 μg/mL) λex = 250 nm, λem = 350 nm; (h) plasma spiked with IS (5 μg/mL
and IS (5 μg/mL) λex = 250 nm, λem = 350; (j) plasma spiked with SN38 (50
samples of NOD/SCID mice after 15 min of i.v. administration of IRT at the d
in plasma samples of NOD/SCID mice after 15 min of i.v. administration of IR
4steam were optimized as 40 °C and 1 h, respectively, to assure
the complete evaporation of organic solvent and thus good
recovery of analytes form plasma. IRT is an ionizable compound
and can be best separated at the mobile phase of pH less than 4
[38]. Therefore, to reduce the pH, 0.5% of orthophosphoric acid
was added to the mobile phase. The good symmetry and shape
of IRT peak with high resolution were achieved with the mobile
phase consisting of water and acetonitrile (57:43 v/v) with pH
adjusted to 3 at the flow rate of 0.8 mL/min. This is contrary to
previous report where low pH of mobile contributed to skewness
and asymmetry in peak shape [39]. Fluorescence detection is
very sensitive, and slight change in the excitation and emission
wavelength was found to affect the response peak. Various
excitation and emission wavelength were screened and peak with
best symmetry, and resolution of IRT was identified at the λex of
250 nm and λem of 350. However, the peak of SN38 specifically
appeared at the λex of 370 nm and λem of 525 nm. Thus, the two
analytes are detected at completely different excitation and
emission wavelengths.50 nm; (b) plasma spiked with IRT (2.5 μg/mL) λex = 250 nm, λem =
SN38 (50 ng/mL) λex = 370 nm, λem = 525 nm; (e) plasma spiked with
(50 ng/mL) λex = 250 nm, λem = 350 nm; (g) plasma spiked with IS
) λex = 370 nm, λem = 525 nm; (i) plasma spiked with IRT (2.5 μg/mL)
ng/mL) λex = 370 nm, λem = 525 nm; (k) IRT concentration in plasma
ose of 20 mg/kg, λex = 250 nm, λem = 350 nm; (l) SN38 concentration
T at the dose of 20 mg/kg, λex = 370 nm, λem = 525 nm
Figure 3. Calibration curves of IRT and SN38 in NOD/SCID ice
plasma
Table 2. Parameters of linear regression analysis
IRT SN38
Linearity range 0.1–10 μg/mL 5–500 ng/mL
Regression equation Y = 1.571x − 0.078 Y = 0.201x + 25.49
Regression coefficient (R2) 0.999 0.997
Slope 1.571 0.201
Intercept 0.078 25.49
Table 3. Intra-day and Inter-day precision and accuracy of IRT (QC
samples)
IRT conc.
(ng/mL)
Intra-day Inter-day
Mean ± SD %
CV
%
Accuracy
Mean ± SD %
CV
%
Accuracy
0.5 0.48 ± 0.06 14.19 95.67 0.52 ± 0.03 7.42 104.1
2.5 2.17 ± 0.23 10.74 86.82 2.07 ± 0.11 5.40 83.02
5 4.80 ± 0.31 6.56 96.10 5.11 ± 0.07 1.52 102.35
Table 4. Intra-day and inter-day precision and accuracy of SN38 (QC
samples)
SN38 conc.
(ng/mL)
Intra-day Inter-day
Mean ± SD %
CV
%
Accuracy
Mean ± SD %
CV
%
Accuracy
10 9.33 ± 1.33 14.30 93.36 10.49 ± 0.36 3.51 104.98
50 54.14 ± 7.25 13.39 108.29 49.49 ± 1.51 3.06 98.99
250 242.98 ± 13.5 5.55 97.19 242.98 ± 4.16 1.71 97.19
Table 5. Percentage recovery of IRT and SN38 from QC samples
IRT conc. (μg/mL) % Recovery SN38 (ng/mL) % Recovery
0.5 91.14 ± 3.26 10 87.19 ± 8.13
2.5 89.23 ± 5.64 50 93.91 ± 4.82
5 90.48 ± 7.60 250 97. 41 ± 5.37
IS (5 μg/mL) 95.31 ± 3.29 IS (5 μg/mL) 95.31 ± 3.29
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3.2.1 Selectivity. The selectivity of the method is the ability
to distinguish and quantify the analyte in the presence of other
component in plasma samples. The chromatograms were as fol-
lows: (a) blank plasma λex = 250 nm, λem = 350 nm; (b) plasma
spiked with IRT (2.5 μg/mL) λex = 250 nm, λem = 350 nm; (c)
blank plasma λex = 370 nm, λem = 525 nm; (d) plasma spiked
with SN38 (50 ng/mL) λex = 370 nm, λem = 525 nm; (e) plasma
spiked with IRT (2.5 μg/mL) λex = 370 nm, λem = 525 nm; (f)
plasma spiked with SN38 (50 ng/mL) λex = 250 nm, λem =
350 nm; (g) plasma spiked with IS (5 μg/mL) λex = 250 nm,
λem = 350 nm; (h) plasma spiked with IS (5 μg/mL) λex =
370 nm, λem = 525 nm; (i) plasma spiked with IRT (2.5 μg/mL)
and IS (5 μg/mL) λex = 250 nm, λem = 350; (j) plasma spiked
with SN38 (50 ng/mL) λex = 370 nm, λem = 525 nm; (k) IRT
concentration in plasma samples of NOD/SCID mice after
15 min of i.v. administration of IRT at the dose of 20 mg/kg,
λex = 250 nm, λem = 350 nm; and (l) SN38 concentration in
plasma samples of NOD/SCID mice after 15 min of i.v. adminis-
tration of IRT at the dose of 20 mg/kg, λex = 370 nm, λem =
525 nm (Figure 2). There was no interference observed in the de-
termination of IRT and SN38 from plasma component. The de-
tection of peaks of IRT and SN38 was wavelength specific. IRT
was detected at λex = 250 nm and λem = 350 nm while SN38
was detected at λex = 370 nm and λem = 525 nm. However, no
peaks were observed for IRT at λex = 370 nm and λem =
525 nm and SN38 at λex = 250 nm and λem = 350 nm, respec-
tively (Figure 2). Flurbiprofen was selected as internal standard
as it was detected at both the excitation and emission wave-
lengths and could thus act as internal standard for both the
analytes. The retention times of IRT and SN38 were found to
be 5.8 ± 0.3 and 6.3 ± 0.25 min, respectively, while the inter-
nal standard eluted at 22.3 ± 0.4 min.
3.2.2 Calibration Curve, LLOQ and LOD. A good linearity
of the curve was observed in the range of 0.1–10 μg/mL for
IRT and 5–500 ng/mL for SN38 as seen in Figure 3a and b,
respectively. The parameters obtained from linear regression
are given in Table 2. The calculated regression equation for
IRT and SN38 was Y = 1.571x − 0.078 and Y = 0.201x +
25.49, respectively (Table 2). The regression coefficient (R2)
value of 0.999 for IRT and 0.997 for SN38 from calibration
curve presents the goodness of fit of the calibration curve.
The LLOQ and LOD for IRT were found to be 0.1 μg/mL
and 0.065 μg/mL, respectively, whereas for SN38 LLOQ was
5 ng/mL and LOD was 2 ng/mL, respectively.
3.2.3 Accuracy, Precision, and Recovery. The intra-day
and inter-day precisions for both IRT and SN38 were found
within in the prescribed limits of % CV less than 15 (Tables 3
and 4). The results from accuracy studies showed that accu-
racy values falls in between the range of 85%–115% and the
developed method was accurate to determine the amount of
IRT and SN38 in plasma. The percentage recovery from
plasma samples at QC concentrations were 91.14%, 89.23%,
and 90.48% for IRT and 87.19%, 93.91%, and 97.41%, re-
spectively, for SN38 (Table 5). The recovery of IS was found
to be above 95%.
3.2.4 Dilution Test. Dilution integrity was validated, and the
final concentration was back calculated by applying the dilu-
tion factor and was found to be not deviating from the nomi-
nal concentration by more than 15%. Thus, dilution of sample
did not impact precision and accuracy of the method.
3.2.5 Stability. The analyte in plasma showed good stability
after being stored for 2 h at room temperature and 48 h in
autosampler when reconstituted in water during bench-top sta-
bility study [40]. The % CV of IRT and SN38 after extraction
from these plasma samples was found to be 12.2% and
10.9%, respectively (i.e., <15%). The IRT and SN38 also5
Development of HPLC method for Irinotecan and SN-38remained stable in the plasma after 2 freeze–thaw cycles [41].
The % CV for IRT and SN38 after 2 freeze–thaw cycles was
9.0% and 10.2%, respectively. After long-term storage of
plasma samples at −80 °C for 2 months, analytes showed %
CV with in limit of 15%. This in agreement with previous lit-
erature reports [41, 42].
3.3 Pharmacokinetic Study. The plasma elimination
profile of IRT was studied in NOD/SCID mice bearing colon
tumor after intravenous administration of IRT at the dose of
20 mg/kg. Plasma concentration at the given time points were
calculated and plotted against time. Data on plasma drug
concentration over time were analyzed using the non-
compartmental analysis with the software WinNonLine
Professional (version 5.0.1, Pharsight Corporation, CA). The
pharmacokinetic parameters calculated for IRT and SN38
including Cmax, t1/2, area under curve (AUC), volume of
distribution (Vd), and clearance (Cl) were calculated and are
given in Table 6. As seen from Figure 4a, a sharp decline in
the plasma concentration of IRT was observed with time and
IRT was found to be completely eliminated from plasma
within 12 h of dose administration. The results are in
compliance with the earlier studies where the fast elimination
of free IRT was observed in xenograft models [43, 44]. The
concentration of SN38 was found to increase initially in first
30 minutes followed by the elimination up to 24h (Figure 4b).
The initial rise in concentration of SN38 can be explained by
the biological conversion of IRT into its active metabolite
SN38 [45]. The t1/2 value of 2.14 h and 1.68 h for IRT andTable 6. Parameter obtained from plasma concentration versus time plot
after intravenous administration of IRT at dose of 20 mg/kg
Sr. no. Parameters IRT SN38
1 Cmax 8.615 ± 1.20 μg/mL 1760.84 ± 210.21 ng/mL
2 t1/2 2.14 h ± 0.12 1.68 ± 0.09 h
3 AUC 13.451 ± 1.37 h*μg/mL 3850.88 ± 920.1 h*ng/mL
4 Vd 4.518 ± 0.213 L/kg —
5 Cl 1.462 ± 0.012 L/h/kg —
igure 4. Plasma elimination profile of (a) IRT and (b) SN38 after intra-
enous administration of IRT at the dose of 20 mg/kg in NOD/SCID
iceF
v
m6SN38, respectively, again suggested the rapid elimination of
IRT and its metabolite from plasma. The AUC of IRT and
SN38 was found to be 13.451 h*μg/mL and 3850.88 h*ng/mL,
respectively. The results indicated short half life, rapid
elimination, and low bioavailability of IRT in NOD/SCID mice.
4. Conclusion
IRT is an extensively used drug in the treatment of various
carcinomas but have many side effects. Alternatively, novel
nanoparticulate formulations have been developed for the safe
and targeted delivery of drug to the tumor site. Human tumor
xenograft models are most common animal models used for
preclinical assessment and evaluating pharmacokinetic, bio-
distribution, and anticancer activity of existing or novel drug
delivery systems. To study the pharmacokinetic profile of IRT
in the plasma of NOD/SCID mice bearing colon tumor, a new,
simple, and sensitive method using HPLC with fluorescence
detection has been developed to quantify IRT and its active
metabolite SN38. The method was successfully developed and
validated in NOD/SCID mice plasma according to the bio-
analytical guidelines by FDA. The developed method has been
effectively applied to study the plasma elimination profile of
IRT and SN38 after intravenous administration of IRT at the
dose of 20 mg/kg and determine pharmacokinetic parameters in
NOD/SCID mice. This method can be used in future PK/PD
modeling studies for IRT and its novel formulations.
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